DBV Technologies reported $15.1M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amarin USD 126.83M 477K Dec/2025
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
DBV Technologies USD 15.1M 1.05M Mar/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
Insmed USD 215.32M 36.77M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
United Therapeutics USD 310.3M 1.7M Jun/2026